Search

everythinglearnresearchcommunity

for

Search:↓

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.

OR101 may effectively treat atopic dermatitis and similar skin conditions.

ATX-101 injections can cause hair loss.

A specific ATR gene mutation is linked to a hereditary oropharyngeal cancer syndrome.

OR-101 shows promise for treating alopecia areata by improving hair growth.

High-throughput LC-MS screening is effective for finding new autotaxin inhibitors for asthma treatment.

Targeting ATM could help manage heart cell enlargement due to pressure overload.

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Tofacitinib may effectively regrow hair in alopecia totalis patients.

A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.

Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.

AS101 reduces hair loss from chemotherapy.

CS12192 effectively treats alopecia areata with better safety than current options.

Atoh1 expression can create new Merkel cells in the skin.

A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.

Allergen-specific immunotherapy can significantly improve hair loss and dermatitis symptoms in severe cases.

Baricitinib was effective in treating both early and late onset alopecia areata.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

JAK inhibitors are effective and safe for treating severe alopecia areata.

The MBTPS2 gene variant c.970+5G>A is a common mutation causing IFAP syndrome.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Atorvastatin is less effective for women with Hashimoto's thyroiditis.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.

CTP-543 is generally safe for treating alopecia areata.

ITK inhibitors may effectively treat alopecia areata.